These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31924201)

  • 41. Early and long-term validation of an algorithm assessing fitness for surgery in patients with postoperative FEV₁ and diffusing capacity of the lung for carbon monoxide < 40%.
    Puente-Maestú L; Villar F; González-Casurrán G; Moreno N; Martínez Y; Simón C; Peñalver R; González-Aragoneses F
    Chest; 2011 Jun; 139(6):1430-1438. PubMed ID: 20930005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
    Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
    Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
    Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
    Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD.
    Kim ES; Kim YT; Kang CH; Park IK; Bae W; Choi SM; Lee J; Park YS; Lee CH; Lee SM; Yim JJ; Kim YW; Han SK; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1317-26. PubMed ID: 27366059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
    Casiraghi M; Guarize J; Sandri A; Maisonneuve P; Brambilla D; Romano R; Galetta D; Petrella F; Gasparri R; Gridelli C; De Marinis F; Spaggiari L
    Clin Lung Cancer; 2019 Mar; 20(2):97-106.e1. PubMed ID: 30446406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
    Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
    World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Impact of neoadjuvant immunotherapy on pulmonary function and perioperative outcomes in patients with resectable non-small cell lung cancer].
    Zhu Y; Li JQ; Chang Q; Qiang HP; Lu JH; Feng H; Shen YC; Qian JL; Chu TQ
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):393-398. PubMed ID: 35144337
    [No Abstract]   [Full Text] [Related]  

  • 50. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
    Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
    Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thoracoscopic lobectomy for non-small-cell lung cancer in patients with impaired pulmonary function: analysis from a national database.
    Bongiolatti S; Gonfiotti A; Vokrri E; Borgianni S; Crisci R; Curcio C; Voltolini L;
    Interact Cardiovasc Thorac Surg; 2020 Jun; 30(6):803-811. PubMed ID: 32249900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
    Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neo-adjuvant Chemo-Radiation to 60 Gray Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer Patients: Evaluation of Trimodality Strategy.
    Appel S; Goldstein J; Perelman M; Rabin T; Urban D; Onn A; Shulimzon TR; Weiss I; Lieberman S; Marom EM; Golan N; Simansky D; Ben-Nun A; Lawrence YR; Bar J; Symon Z
    Isr Med Assoc J; 2017 Oct; 19(10):614-619. PubMed ID: 29103238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of lobectomy in patients with severely compromised lung function (predicted postoperative diffusing capacity of the lung for carbon monoxide % ≤ 40%).
    Paul S; Andrews WG; Nasar A; Port JL; Lee PC; Stiles BM; Altorki NK
    Ann Am Thorac Soc; 2013 Dec; 10(6):616-21. PubMed ID: 24015712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective.
    Rocco G; Nason K; Brunelli A; Varela G; Waddell T; Jones DR
    J Thorac Cardiovasc Surg; 2016 May; 151(5):1235-8. PubMed ID: 26997100
    [No Abstract]   [Full Text] [Related]  

  • 57. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer.
    Carretta A; Ciriaco P; Melloni G; Sayed I; Bandiera A; Ferla L; Puglisi A; Zannini P
    World J Surg; 2008 Dec; 32(12):2636-42. PubMed ID: 18836761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer.
    Abou-Jawde RM; Mekhail T; Adelstein DJ; Rybicki LA; Mazzone PJ; Caroll MA; Rice TW
    Chest; 2005 Jul; 128(1):250-5. PubMed ID: 16002943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.